MYRIAD GENETICS, INC. MYGN Cash Flow

Myriad genetics, inc. (MYGN)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Myriad Genetics, Inc. stockholders
-115,200	-8,300	-20,600	-4,200	6,900	2,600	-700	14,400	9,200	30,900	78,800	8,400	4,300	5,900	-1,200	-	-	-	-	18,700	21,500	24,000	16,000	33,607	36,768	50,360	55,465	44,135	37,893	35,036	30,136	29,142	29,615	28,295	25,099	26,040	27,941	24,191	22,538	53,250	33,251	35,360	30,442
Net Income attributable to Myriad Genetics, Inc. stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization
17,900	18,200	18,200	18,400	18,300	18,000	18,300	15,100	13,000	13,100	13,200	13,300	12,900	12,900	9,200	6,700	6,500	6,700	6,800	6,600	6,400	6,000	6,000	5,509	3,480	2,439	2,372	2,265	2,180	2,244	2,211	2,328	2,303	2,291	2,147	1,878	1,800	1,784	1,757	1,792	1,778	1,735	1,779
Non-cash interest expense
100	100	100	100	1,500	100	-1,300	100	0	0	100	0	100	200	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on disposition of assets
100	0	100	0	0	-100	1,000	300	0	-200	100	100	0	0	200	500	0	0	400	-	-	-	-100	-848	-12	0	-40	-	0	-3	-1	-	-	-	4	-	-	-	-	-129	-302	223	-288
Share-based compensation expense
7,500	7,000	8,800	8,800	9,500	7,500	7,700	7,100	6,700	6,900	6,400	7,200	7,500	7,400	7,800	7,700	7,600	7,600	8,700	14,100	12,600	12,100	6,900	6,597	6,711	6,857	6,935	6,165	6,731	7,104	6,600	6,416	6,588	6,607	6,664	6,373	6,224	6,118	6,373	5,803	4,977	6,618	5,378
Bad debt expense
-	-	-	-	-	-	-	-	-	-	-	-	9,200	10,900	7,200	9,800	9,000	8,500	6,000	8,000	9,500	6,900	7,100	8,232	9,175	10,299	11,494	10,197	8,374	7,534	7,195	7,251	6,902	6,331	4,258	3,845	3,788	4,189	4,360	4,739	4,487	4,829	4,421
Deferred income taxes
16,100	1,700	5,100	-15,600	-700	400	-2,700	-1,400	-1,000	30,600	-4,700	1,200	900	300	-3,200	13,400	-1,700	-18,400	-11,400	-600	2,900	800	-2,700	-6,273	-3,653	1,238	588	-2,380	879	-3,675	-2,224	574	-2,925	-16,488	-14,786	-13,565	-13,708	-13,345	-12,538	-	-	-	-
Unrecognized tax benefits
100	-300	-400	-1,800	5,000	-300	2,600	3,000	5,500	-1,500	-6,700	-2,100	300	200	400	0	-3,900	600	900	200	800	800	300	-3,623	323	962	1,638	230	340	0	130	-	-	-	-	200	648	-529	-467	-	-	-	-
Change in fair value of contingent consideration
2,100	0	700	0	0	-1,000	-400	400	-1,100	13,000	-73,200	-2,800	5,200	-3,700	500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accreted interest on note receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37	2,004	667	666	700	667	666	667	-	-	-	-	-	-	-	-	-	-	-	-
Excess tax benefit from share-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200	600	900	1,700	5,991	4,517	578	14	2,635	1,642	3,160	463	1,996	708	14,449	17,040	14,649	16,489	15,335	12,358	-	-	-	-
Gain on sale of marketable investment securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	537	22	7	38	14	-39	-10	236	298	-64	-73
Changes in assets and liabilities:
Prepaid expenses
-3,700	2,800	-2,600	5,200	-1,200	1,000	-1,800	-600	200	300	-3,200	3,100	-2,600	-500	-7,800	-1,500	11,500	4,200	-7,000	2,500	2,200	-1,700	2,500	4,663	2,644	-701	-1,106	-622	323	-332	-169	-428	-942	-202	368	2,231	-990	-1,775	946	1,145	-3,022	5,856	-3,918
Trade accounts receivable
-15,900	3,100	-16,700	-8,800	26,100	-2,400	3,300	-5,300	1,400	6,800	6,200	-40,800	15,900	18,500	5,900	10,500	17,600	7,500	3,600	2,200	18,300	12,400	1,500	7,093	5,710	8,218	3,379	11,366	25,983	20,591	9,260	16,800	14,806	4,530	-1,150	3,946	10,161	423	388	4,422	3,836	16,942	-3,540
Other receivables
-1,200	200	100	300	-1,500	1,600	300	3,000	-2,700	-1,100	-300	800	800	600	1,800	-100	-4,300	5,500	-200	-1,600	-2,500	-5,900	7,500	1,313	415	1,730	-1,558	1,173	1,199	-982	-690	1,160	536	537	79	-749	948	-51	54	-613	807	204	-420
Inventory
-	500	-3,100	-600	-1,300	-2,600	-3,500	1,000	-4,800	-800	-3,300	-5,300	-3,900	-2,600	13,000	14,400	-3,900	-5,100	9,200	-4,100	8,600	-4,600	900	-	-	-	-	-	-	-	-	1,246	69	623	1,488	-	-	-	-	-	-	-	-
Prepaid taxes
700	1,700	-2,100	22,100	-100	-500	3,600	-	-5,700	-500	8,900	200	-4,000	-600	1,000	-11,500	-12,700	10,800	17,200	0	-5,600	-13,100	5,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
9,200	-2,000	-9,300	9,200	-7,800	8,100	-8,400	6,000	-5,000	2,600	400	-5,000	4,000	3,000	-5,000	-	-2,800	1,200	-5,300	3,300	-200	-8,800	2,600	4,135	-5,099	-1,149	613	5,903	-1,337	2,489	945	2,207	-954	-926	-1,576	3,966	-1,859	-192	-1,628	1,844	-2,377	1,755	-6,529
Accrued liabilities
-3,600	-10,100	-1,700	100	6,100	-300	-4,400	4,000	3,200	0	-5,800	1,800	4,400	5,000	-10,000	-2,400	3,400	5,200	-5,700	-1,900	3,700	600	-15,800	5,333	-3,743	-13,546	15,056	6,020	9,160	-13,804	10,224	5,068	4,105	3,518	-1,473	343	2,043	977	-2,439	2,408	1,883	-37	-4,647
Deferred revenue
-	-	-	-100	-100	-100	-200	0	-800	100	600	-100	500	1,500	-1,000	-	-	-	-100	200	-500	400	300	-1,023	-1,986	3,057	-1,148	-	310	-554	1,221	685	-1,059	1,367	-245	-	-	-	-	-	-	-	-
Net cash provided by operating activities
16,800	-1,900	15,800	31,500	6,600	37,800	7,800	47,900	11,500	33,000	23,500	36,600	41,100	31,400	-2,900	56,400	44,100	36,000	29,800	51,000	29,900	52,600	7,000	40,920	11,249	47,549	90,482	63,034	37,396	22,114	51,356	41,703	40,747	27,530	31,824	36,373	28,036	37,125	29,296	46,522	42,656	42,727	23,181
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures
3,000	3,400	1,400	1,400	3,100	2,800	1,300	1,800	2,900	2,100	1,600	700	1,500	2,400	1,500	2,200	700	1,100	1,000	2,000	4,400	6,000	11,500	4,647	1,555	2,833	5,265	2,818	1,574	4,547	2,461	2,192	2,000	3,107	2,109	610	158	1,065	1,959	827	1,148	4,343	1,577
Acquisitions, net of cash acquired
-	-	-	0	0	-1,100	279,600	-	-	-	-	0	0	3,100	213,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	799	-	-	-	-	-	-	-	-
Purchases of marketable investment securities
15,800	21,900	23,100	21,500	20,400	22,200	14,400	1,500	18,100	29,800	31,500	12,900	25,600	16,800	32,200	33,100	30,700	78,900	21,800	25,600	32,500	16,700	5,900	56,349	2,790	42,519	60,142	162,026	42,510	112,361	126,903	97,213	130,996	118,576	41,282	86,190	110,388	181,056	47,519	146,517	110,832	165,041	55,168
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,100	22,700	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of an acquisition option
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8,000	-	-	-	-	-	-	-	-
Issuance of note receivable (Crescendo)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	17,000	-	-	-	-	-	-	-	-
Proceeds from maturities and sales of marketable investment securities
20,800	18,100	17,400	27,400	19,700	15,800	16,300	12,200	20,300	27,300	17,900	17,900	34,000	20,200	88,700	28,500	15,300	39,500	31,800	24,800	60,300	12,900	67,600	42,635	226,833	56,186	56,846	85,905	92,165	82,871	124,359	91,231	89,179	138,168	66,658	105,779	153,026	131,116	66,151	159,315	98,251	92,962	58,057
Net cash provided by (used in) investing activities
23,300	-7,200	-7,100	4,500	-3,800	-8,100	-279,000	8,900	-700	-4,600	-15,200	4,300	9,500	-2,100	-158,000	-43,800	-16,100	-40,500	9,000	-2,800	24,900	-8,700	27,500	-18,330	-1,043	10,834	-8,561	-83,939	48,081	-34,037	-5,005	-8,174	-43,817	15,635	-2,532	-60,938	42,480	-52,605	16,673	11,971	-13,429	-76,522	1,312
Net proceeds from common stock issued under share-based compensation plans
200	1,700	-400	2,200	2,000	2,400	2,100	18,700	11,900	4,600	1,700	4,700	300	2,900	-1,900	8,400	1,000	62,100	22,800	4,400	5,400	5,100	15,100	17,644	40,794	5,571	791	32,294	1,603	15,287	8,616	6,971	10,371	6,843	844	17,102	775	6,439	744	3,591	12,491	3,030	3,193
Payment of contingent consideration recognized at acquisition
0	600	3,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	199,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from revolving credit facility
-	-	-	0	0	50,000	290,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of revolving credit facility
0	0	8,600	30,000	10,000	35,000	40,000	60,000	27,000	31,000	25,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Excess tax benefit from share-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200	600	900	1,700	5,991	4,517	578	14	2,635	1,642	3,160	463	1,996	708	14,449	17,040	14,649	16,489	15,335	12,358	-	-	-	-
Repurchase and retirement of common stock
-	-	-	-	-	-	-	-	-	-	-	0	0	10,300	21,300	54,700	45,000	24,900	38,000	44,800	62,000	58,300	45,600	65,686	41,890	77,808	102,316	21,595	44,822	33,684	46,199	60,996	12,005	18,285	37,181	21,883	88,071	61,930	28,606	-	-	-	-
Net cash provided by (used in) financing activities
200	1,100	-12,300	-27,800	-9,400	-32,600	252,100	-41,300	-4,300	-26,100	-23,300	-63,300	-36,700	-4,000	175,800	-64,200	-42,200	53,300	-15,200	-40,200	-56,000	-52,300	-28,800	-42,051	3,421	-71,659	-101,511	13,334	-41,577	-15,237	-37,120	-52,029	-926	3,007	-19,297	9,868	-70,807	-40,156	-15,504	-67,802	12,491	3,030	3,193
Effect of foreign exchange rates on cash and cash equivalents
-2,000	800	300	100	900	200	1,500	-2,000	2,200	-1,500	500	1,000	1,900	-4,200	3,500	-400	0	-1,500	-300	900	-3,300	-1,700	-700	-1,564	572	-112	504	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
39,800	-8,700	-3,300	8,300	-5,700	-2,700	-17,600	13,500	8,700	800	-14,500	-21,400	15,800	21,100	18,400	-52,000	-14,200	47,300	23,300	8,900	-4,500	-10,100	5,000	-21,025	14,199	-13,388	-19,086	-8,271	43,900	-27,160	9,231	-18,500	-3,996	46,172	9,995	-14,697	-291	-55,636	30,465	-9,309	41,718	-30,765	27,686